MSACL 2017 EU
Sep 10, 2017
- Sep 14, 2017
Previous MSACL events
What you do in clinical research changes the world one life at a time
Welcome to the on-demand highlights from MSACL 2016 held in Salzburg, Austria, 13–15 September 2016. From the comfort of your desk, download our poster presentations and seminars from MSACL 2016.
Join the experience and hear expert testimonials and discover the latest developments in workflow automation, online sample preparation, and simplified data analysis to help solve your toughest analytical challenges
Microsampling techniques and LC-MS/MS: therapeutic drug monitoring research to help personalize medicine for our children
Giuliana Cangemi, PhD, MSC - Istituto Giannina Gaslini Children's Hospital in Genoa, Italy
Neonates, infants, and children undergo major and rapid age-related physiologic and biochemical changes, especially during the first year of life, resulting in different clinical pharmacokinetic (PK) and pharmacodynamic (PD) parameters compared to adults. Approximately 10% of all drugs prescribed are for children, making the majority of prescriptions off-label. Premature infants in neonatal intensive care units can receive up to twenty drugs during their hospital stay, and their blood often needs to be monitored by the laboratory. The availability of reliable analytical methods and microsampling techniques is thus crucial for therapeutic drug monitoring (TDM) and for conducting clinical PK studies in pediatrics, especially for low-birth-weight neonates. Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) is the analytical technique of choice, guaranteeing high specificity, accuracy, and reproducibility. Sensitivity is of fundamental importance, not only to limit blood sample volume, but also to simplify sample preparation procedures and improve throughput. In this context, alternative sampling strategies such as dried blood spot, volumetric microsampling devices, and dried plasma spot have an emerging role. This workshop will explore analytical challenges and opportunities and possible application to routine clinical analysis.
Speeding up the cancer biomarker discovery: Advanced Clinical Proteomics workflow with High Resolution MS
Sebastien Gallien, former researcher at CRP-Santé LIH Luxembourg Institute of Health, Thermo Fisher Scientific
Adoption of cancer biomarkers in clinical labs has been plagued by the speed with which these biomarkers are discovered and validated for clinical use. Clinical proteomics approaches where the use of predefined set of surrogate peptides for proteins has been helpful in systematically identifying these markers. Targeted analyses using parallel reaction monitoring (PRM), performed on high resolution and accurate-mass (HRAM) quadrupole-Orbitrap mass spectrometers, present the selectivity and sensitivity to confidently quantify peptides in complex samples. The internal standards (IS) used for isotope dilution quantification were recently leveraged to actually drive the acquisition (“internal standard triggered-parallel reaction monitoring”, IS-PRM), thus improving the acquisition efficiency. The application of this advanced PRM method was investigated for clinical proteomics, involving high-throughput screening and accurate quantification. Analyses of lung cancer markers in clinical plasma samples illustrating an advanced workflow automation and improved portability of the developed assays will be discussed in detail. Learn what it takes to uncover biomarkers faster for future use in predictive diagnostic.